These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 16644473)

  • 1. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
    Popma SH; Griswold DE; Li L
    Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS; Anasetti C; Tso JY
    J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
    Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
    Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
    J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
    Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
    Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
    Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
    J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
    Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
    J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A humanised mouse model of cytokine release: comparison of CD3-specific antibody fragments.
    Malcolm SL; Smith EL; Bourne T; Shaw S
    J Immunol Methods; 2012 Oct; 384(1-2):33-42. PubMed ID: 22796190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody.
    Sawchuk SS; Gates R; Hirsch R
    Transplantation; 1995 Dec; 60(11):1331-7. PubMed ID: 8525530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
    Van Lier RA; Boot JH; De Groot ER; Aarden LA
    Eur J Immunol; 1987 Nov; 17(11):1599-604. PubMed ID: 2960543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
    Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
    J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage inflammatory protein-1 alpha rapidly modulates its receptors and inhibits the anti-CD3 mAb-mediated proliferation of T lymphocytes.
    Zhou Z; Kim YJ; Pollok K; Hurtado J; Lee JK; Broxmeyer HE; Kwon BS
    J Immunol; 1993 Oct; 151(8):4333-41. PubMed ID: 8409405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a 33-kDa antigen Tm 1 on lymphocyte surface after modulation of cell surface antigens by IgM monoclonal antibody.
    Hara T; Jung LK; Fu SM
    J Immunol; 1988 Feb; 140(4):1028-33. PubMed ID: 2963858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.